🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

672 results for “Nan” Clear

  1. LVIVO-TaVec400 product

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE)

    phase 1 mab active

    1 trial

  2. Low dose ET019002- T Cells

    The First People's Hospital of Lianyungang

    B-Cell Malignancies

    phase 1 mab active

    1 trial

  3. MKC-1

    CASI Pharmaceuticals

    Hematological Malignancies

    phase 1 small molecule completed

    1 trial

  4. MLN0128

    Takeda

    Advanced Solid Malignancies

    phase 1 small molecule completed

    2 trials

  5. MLN0264

    Takeda

    Advanced Gastrointestinal Malignancies

    phase 1 small molecule completed

    1 trial

  6. MLN2480

    Takeda

    Advanced Nonhematologic Malignancies

    phase 1 small molecule completed

    1 trial

  7. MLN7243

    Takeda

    Advanced Malignant Solid Tumors

    phase 1 small molecule terminated

    1 trial

  8. Menopur 150 international units

    NORTHWEST BIOTHERAPEUTICS INC

    Pregnancy

    phase 1 small molecule terminated

    1 trial

  9. Midazolam

    ENANTA PHARMACEUTICALS INC

    NASH

    phase 1 small molecule completed

    1 trial

  10. Multiple-Ascending Doses of 2-Methoxyestradiol in Healthy Non-Pregnant Female Participants.

    Laboratorios Tillomed Spain S.L.U

    No medical condition.

    phase 1 other active

    1 trial

  11. NTQ5082 capsule

    Nanjing Chia-tai Tianqing Pharmaceutical

    Complement-mediated Hemolytic Diseases

    phase 1 small molecule active

    1 trial

  12. Nanosensor

    United Therapeutics Europe Ltd

    MItochondrial Myopathies

    phase 1 other active

    1 trial

  13. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Advanced Malignant Solid Tumors

    phase 1 small molecule completed

    3 trials

  14. OMP-305B83

    Mereo BioPharma Group plc

    Advanced Solid Tumor Malignancies

    phase 1 small molecule completed

    1 trial

  15. OMP-336B11

    Mereo BioPharma Group plc

    Locally Advanced Malignant Neoplasm

    phase 1 small molecule terminated

    1 trial

  16. OMP-52M51

    Mereo BioPharma Group plc

    Relapsed or Refractory Lymphoid Malignancies

    phase 1 small molecule completed

    1 trial

  17. ONC206 Powder

    AXIM BIOTECHNOLOGIES, INC.

    Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors

    phase 1 small molecule active

    1 trial

  18. Obatoclax mesylate (GX15-070MS)

    Teva Pharma GmbH

    Hematological Malignancies

    phase 1 small molecule completed

    1 trial

  19. Olaratumab

    Eli Lilly and Company

    Malignancy

    phase 1 mab completed

    1 trial

  20. Oncolytic Virus SDJ001

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Malignant Tumor

    phase 1 small molecule active

    1 trial

  21. PBCAR19B

    Chongqing Precision Biotech Co., Ltd

    CD19 Expressing Malignancies

    phase 1 gene therapy completed

    1 trial

  22. PEGylated recombinant candida urate oxidase

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gout

    phase 1 small molecule active

    1 trial

  23. PEGylated recombinant human hyaluronidase PH20

    HALOZYME THERAPEUTICS, INC.

    Non-small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  24. PEGylated recombinant human interferon alpha-2b injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatitis B, Chronic

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources